These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29848371)

  • 1. In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series.
    Xu MJ; Wu S; Daud AI; Yu SS; Yom SS
    J Immunother Cancer; 2018 May; 6(1):43. PubMed ID: 29848371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Merkel Cell Carcinoma.
    Nagase K; Narisawa Y
    Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series.
    LoPiccolo J; Schollenberger MD; Dakhil S; Rosner S; Ali O; Sharfman WH; Silk AW; Bhatia S; Lipson EJ
    J Immunother Cancer; 2019 Jul; 7(1):170. PubMed ID: 31287031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine release syndrome after radiation therapy: case report and review of the literature.
    Barker CA; Kim SK; Budhu S; Matsoukas K; Daniyan AF; D'Angelo SP
    J Immunother Cancer; 2018 Jan; 6(1):1. PubMed ID: 29298730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases.
    Knackstedt R; Sussman TA; McCahon L; Song JM; Funchain P; Gastman B
    Ann Oncol; 2019 Aug; 30(8):1399-1400. PubMed ID: 31250007
    [No Abstract]   [Full Text] [Related]  

  • 6. An autoimmune-based, paraneoplastic neurologic syndrome following checkpoint inhibition and concurrent radiotherapy for merkel cell carcinoma: case report.
    Sherry AD; Bezzerides M; Khattab MH; Luo G; Ancell KK; Kirschner AN
    Strahlenther Onkol; 2020 Jul; 196(7):664-670. PubMed ID: 32006066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma.
    Winkler JK; Bender C; Kratochwil C; Enk A; Hassel JC
    Br J Dermatol; 2017 Jan; 176(1):216-219. PubMed ID: 27038231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
    D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; von Heydebreck A; Güzel G; Nghiem P
    ESMO Open; 2024 May; 9(5):103461. PubMed ID: 38744102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts' recommendations.
    Munhoz RR; Cayol F; Corrales L; Gerson R; Tilli M; Barreto EO; Sánchez Castillo JO; Schmerling RA; Cinat G
    Cancer Immunol Immunother; 2021 Apr; 70(4):1031-1036. PubMed ID: 33104838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.
    Ascierto PA; Orlova K; Grignani G; Dudzisz-Śledź M; Fenig E; Chiarion Sileni V; Fazio N; Samimi M; Mortier L; Gebhardt C; Kramkimel N; Steven N; Bechter O; Arance A; Benincasa E; Kostkova L; Costa N; Lorigan P
    Int J Cancer; 2021 Dec; 149(11):1926-1934. PubMed ID: 34310716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
    Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A
    Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor and Anti-Hepatitis C Viral Response After Administration of the Anti-Programmed Death 1 Antibody Pembrolizumab.
    Jang S; Venna S
    J Oncol Pract; 2017 Jul; 13(7):462-464. PubMed ID: 28562196
    [No Abstract]   [Full Text] [Related]  

  • 13. Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy.
    Marchand A; Kervarrec T; Bhatia S; Samimi M
    Expert Rev Anticancer Ther; 2020 Dec; 20(12):1093-1106. PubMed ID: 33044876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
    Samimi M
    Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT-confirmed complete response.
    Zijlker LP; Levy S; Wolters W; van Thienen JV; van Akkooi ACJ; Tesselaar MET
    Cancer; 2024 Feb; 130(3):433-438. PubMed ID: 37788133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma.
    Fischer S; Hasan Ali O; Jochum W; Kluckert T; Flatz L; Siano M
    Oncol Res Treat; 2018; 41(6):391-394. PubMed ID: 29734143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.
    Cardis MA; Jiang H; Strauss J; Gulley JL; Brownell I
    BMC Cancer; 2019 Jun; 19(1):539. PubMed ID: 31164102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan.
    Chang WC; Lin AY; Hsu JC; Wu CE; Goh C; Chou P; Kuo K; Chang A; Palencia R
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1399. PubMed ID: 33934577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
    Paulson KG; Bhatia S
    J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
    Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
    J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.